Compare FNWB & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | STIM |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 105.5M |
| IPO Year | 2015 | 2018 |
| Metric | FNWB | STIM |
|---|---|---|
| Price | $9.38 | $1.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.50 | $7.00 |
| AVG Volume (30 Days) | 33.5K | ★ 1.2M |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $54,052,000.00 | ★ $129,873,000.00 |
| Revenue This Year | $31.86 | $101.67 |
| Revenue Next Year | $10.64 | $10.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.47 | ★ 78.61 |
| 52 Week Low | $6.05 | $1.25 |
| 52 Week High | $12.10 | $5.92 |
| Indicator | FNWB | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 41.69 |
| Support Level | $9.88 | $1.26 |
| Resistance Level | $10.08 | $1.44 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 8.07 | 25.47 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.